The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Looks like Blue Prism hit its 50-day moving average and wasn't able to hold. I think the steep decline (in terms of percentage) this week is the result of traders playing the short-term technicals. I remain bullish on the long-term fundamentals. Patiently holding through the choppy waters in the short-run.
@joatmon, Warren buffet sold shares in Blue Prism? I never heard that they even had shares to begin with.
Time for blast off! Let's gooooo!!!!
Thanks @cascudi. So if only 2.23% of the shares are being sold short (at least through institutional money), it doesn't seem like a short squeeze could be taking place. Would you agree?
@joatman, it's both. Blue Prism partners with IBM by providing integrations on the digital exchange. That said, IBM is listed separately as a competitor on the latest Gartner chart for RPA. Since they are in the lower left quadrant (ie the worst quadrant) and Blue Prism is a "leader" in the top right quadrant (ie the best quadrant), I would not say that IBM is a serious threat to Blue Prism at this point.
Those statements are not mutually exclusive @banner76. One month ago, Blue Prism was my biggest holding (and still is for the record), and now is also an optimal time to buy once the point of equilibrium has been reached. Where's the disconnect?
@cascudi, I can't see what the short interest is on the stock over here in the U.S. Do you have any info on that?
The comments on this page have dried up, and so has trading volume. We've reached exhaustian.....the point at which the sellers have finished their panic selling and the buyers have already gone all in. We're now at equilibrium.
This is the time I like to buy. The dust has cleared and what's left is an incredible business selling at a 2/3 discount. The stock has now been de-risked as the pros like to say.
The 2021 Gartner Magic Quadrant for RPA listed Blue Prism as a leader yet again along with 3 others (UiPath, Automation Anywhere, and Microsoft). There were also 14 other RPA vendors listed in the other 3 non-leader quadrants. This clearly demonstrates that while the competition is strong among the "Big 4" (formerly "Big 3" before Microsoft), Blue Prism is right there in the mix.
I'll say it yet again......
- 10% market share in an industry growing at 30% CAGR
- 1/3 UiPath's revenue
- 1/3 UiPath's social media followers
- 0.2 stars out of 5 lower than UiPath in reviews from customers (per Gartner Peer Insights)
- Trading at 1/32nd of the valuation of UiPath
Blue Prism is a BUY BUY BUY. Last chance to pile in before we go to the moon!
@joatman, that should benefit both companies. Alteryx (AYX) has also had a bit of a hard time with their share price lately.
My guess is both!
@joatmon, nice to see some positive news. There will obviously be a lag until this is reflected in the growth numbers, but it demonstrates the sleeping giant that will awake in the next year or two. The smart money is buying now.
That's what I'm talking about @Henrygobaker! The moving averages should tell a better technical story within 10 weeks.....arguably within 6 weeks is my guess.
Thank you @Lsoc85!
Forgive my ignorance here, but does that mean that Systematica has 1% of the total short position on Blue Prism? Or 1% of Systematica's investments is allocated to Blue Prism shorts?
I'm a big believer in Blue Prism, so I may be the wrong person to ask haha. But the bear case against the company includes:
1) Slowing revenue growth from new customers
2) UiPath's IPO loaded them up with capital to out invest Blue Prism in future product development. Those lowest on Blue Prism are assuming this makes Blue Prism go obsolete entirely - which is a wild stretch in my opinion.
3) They failed to list in the U.S. despite tipping their hand last December that they were exploring it. Everyone assumed they would by now. So the delay has caused some investors to give up on Blue Prism.
All of those points have an upside to them.......what if their growth rebounds? What if their increased investment in R&D and product roles leads to a much better offering.......what if they list in the U.S. and attract capital to invest more and grow faster. To me those are upside surprises in hiding as the worst is already baked into the current share price.
Yesterday, about 1M in pre-arranged shares were issued dating back to the Thoughtonomy deal. It wasn't a capital raising issuance though. Diluted the existing share pool (95M) by about 1%.
Well, I don't exactly get what Bank of America is doing so who knows. The extra shares is only about 1%+ of dilution to existing shareholders, so that in itself isn't a killer.
Today, it was announced that Blue Prism issued 1M new shares as part of the Thoughtonomy acquisition. There's a 6 month lock-up until they can be sold, and another 6 month restriction after that to ensure "orderly" liquidation (or something).
I noticed that Bank of America's swaps had a big execution date of today (7/19/21), the same day that shares were issued and another big execution date is set for January 2022 when the lockup expires. It clearly seems that Bank of America's change in ownership and swaps are related to these dates.
Can someone smarter than me explain how these two things could be connected and what Bank of America could be trying to hedge via their swaps?
I completely agree. The Brits need to think like American capitalists. The only question for shareholders is: what price would they be bought out at. If they were to sell at anything less than 2x today's price, there would be a lot of shareholders that would be forced to lock in big losses. Hopefully that's not the case here.